Effect of Some Oral Hypoglycemic Agents on Hepatic Protein Synthesis

Total Page:16

File Type:pdf, Size:1020Kb

Effect of Some Oral Hypoglycemic Agents on Hepatic Protein Synthesis Loyola University Chicago Loyola eCommons Master's Theses Theses and Dissertations 1965 Effect of Some Oral Hypoglycemic Agents on Hepatic Protein Synthesis Lawrence Dechatelet Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_theses Part of the Biochemistry, Biophysics, and Structural Biology Commons Recommended Citation Dechatelet, Lawrence, "Effect of Some Oral Hypoglycemic Agents on Hepatic Protein Synthesis" (1965). Master's Theses. 1976. https://ecommons.luc.edu/luc_theses/1976 This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. Copyright © 1965 Lawrence Dechatelet EJ'FEC'l' OF SOME ORAL HYPOGLYCEMIC ABUTS ON HEPATIC PROTEIN SYNTHESIS by LAWRENCB R. DECHA'l'ELBT A Thesis Submitted to the 'aculty of the Graduate School of Loyola University in Partial Fulfillment of the Requirements for the Degree of Master of Science June 1965 LIFE Lawrence Robert DeChatelet was born in Chicago, Illinois on December 24, 1940. In June 1959, he graduated from Saint Ignatius High School, Chicago, Illinois and then attended Loyola University, Chicago, Illinois, from where he received the Degree of Bachelor of Science in Chemistry in June, 1963. In September 1963, the author began his advanced studies in the Graduate School of Loyola University, Department of Bio­ chemistry. From September 1963, to September 1964, he held the position of Research Assistant in the Department of Biochemistry at the Stritch School of medicine of Loyola University, Chicago, Illinois. The position was supported financially by a grant from the Chicago Heart Association. From September 1964, to the pres­ ent he was a Cooperative Graduate Fellow of the National Science Foundation, Washington, D.C. On December 26, 1964, the author married the former Miss Mary Patricia Dolan of Chicago, Illinois. ACKNOWLEDGEMENT The author wishes to thank his advisor, Dr. H.J. Me Donald, not only for his time and effort in developing this thesis, but perhaps more importantly, for his role in developing the author's scientific maturity. Thanks are due likewise to the entire staff of the de­ partment of Biochemistry and Biophysics as well as to my fellow graduate students for their many helpful comments and suggestions Finally, an inexpressible debt is due to my wife Pat, who willingly put up with the many inconveniences that are the 10 of a graduate student's wife. Without her encouragement, this thesis might well have never been written. TABLE OF CONTENTS CHAPTER -PAGE I DIABETES AND THE ACTION OF INSULIN. • • • • • • • 1 II THE CHEMISTRY OF INSULIN AND THE ORAL HYPOGLYCEMIC AGENTS • • • • • • • • • • • • • • • 16 III MATERIALS AND METHODS • • • • • • • • • • • • • • 35 General Experimental Procedure • • • • • • • 35 Chemicals ••• • • • • • • • • • • • • • • • 37 Composition of Solutions • • • • • • • • • • 40 Preparation of Liver Homogenates • • • • • • 42 Isolation of Beta-Lipoprotein. • • • • • • • 43 Cardiac Puncture • • • • • • • • • • • • • • 46 Protein Isolation. • • • • • • • • • • • • • 4'7 Protein Determination. • • • • • • • • • 48 14 C 02 Collection and Measurement • • • • • • 52 IV EXPERIMENTAL RESULTS • • • • • • • • • • • • • • 56 Experiment 1: Change in pH During the Course of the Incubation • • • • •• 56 .K.xperiment 2: The Incorporation of Leucine -C14 into Beta-Lipoprotein: Effect of Differing Isotope. 58 Experiment 3: The Incorporation of Leucine _C14 into Beta-Lipoprotein: Effect of Tolbutamide Addition and of Omission of Premix • • 60 Experiment 4: Distribution of Radioactivity in Various Protein Fractions. 62 CHAPTER -PAGE IV Experiment 5: A Comparison of the Effect of Tolbutamide and Phenethyl­ biguanide on the Incorporation of Leucine into Various Protein Fractions. • • • • • • • • • • 66 Experiment 6: Effect of Tolbutamide and Phen­ ethylbiguanide on c140 Produc- 2 tion from Leucine-l-C14• • •• 70 Experiment 7: The Effect of Three Hypo- glycemic Agents on Leucine Anabolism and Catabolism • • • '{3 Experiment 8: The Etfect of the Concentra- tion of Phenethylbiguan1de on 140 C 2 Evolution. • • • • • •• 75 Experiments 9 and 10: The Effect of the Concentrati en of Phenethylb1guanide on c140 2 Evolution and Protein Incorpo- ration • • • • • • • • • • •• 78 Experiment 11: The Effect of the Concentra­ tion of Tolbutamide on C140 2 Evolution and Protein Incorpo- ration • • • • • • • • • • •• 78 Experiment 12: The Effect of Glucose on Inhi­ bition by Hypoglycemic Agents of Leucine Anabolism and Catabolism • • • • • • • • •• 87 SUMMARY AND CONCLUSIONS. • • • • • • • • • • • • • go APPENDIX ••• • • • • • • • • • • • • • • . • • 92 BIBLIOGRAPHY • • • • • • • • • • • • • • • • • • • 96 LIST OF TABLES TABLE -PAGE I STUDIES OF THE INFLUENCE OF INSULIN ON PROTEIN METABOLISM • • • • • • • • • • • • • • • • • •• 11 II THE ARYLSULrONYLUREAS. • • • • • • • • • • • • • 22 III GUAHIDlNE AND SOME DERIVATIVES • • • • • • • • • 23 IV COMPOSITION OF PREMIX. • • • • • • • • • • • • • 41 V STANDARD CURVE DATA FOR PROTEIN DETERMINATION.. 50 VI SELP-ABSORPTIOH CORRECTIONS FOR BaC03. • • • •• 55 VII THE pH OF THE INCUBATION MIXTURES. • • • • • • • VIII INCORPORATION OF LEUCINE INTO BETA-LIPOPROTEIH: EFFECT OF SPECIFIC ACTIVITY OF ISOTOPE • • • •• 59 IX INCORPORATION OF LEUCINE INTO BETA-LIPOPROTEIN: EfFECT OF TOLBUTAMIDE ADDITION AND OF OMISSION OF PREMIX. • • • • • • • • • . • • • • • • • • • 61 X DISTRIBUTION OF RADIOACTIVITY. • • • • • • • •• 65 XI DISTRIBUTION OF RADIOACTIVITY: INCUBATION WITH TOLBUTAMIDE AND PHENETHYLBIGUANIDE 6'{ XII SUMMARY or EXPERIMENTS 4 AND 5 • • • • • • • • • 68 XIII CO2 RELEASE AND PROTEIN INCORPORATION FROM EXPERI~ 6 • • • • • • • • • • • • • • • • • • 71 XIV EFFECT 01' THREE AGENTS ON ANABOLISM AND CATABOLISM OF LEUCINE. • • • • • • • • • • • • • '{4 xv EFFECT OF CONCENTRATION OF PHENE'l'HYLBIGUANIDE ON 14 C O2 EVOLUTION (EXPERIMENT 8) • • • • • • • •• '(6 TABLI!: -PAGE XVJC ltFFECT OF CONCENTRATJCON OF PHENETHYLBIGUANJCDE ON C140 It''O~U'l'JCON (EXPERJCMEN'l' 9). • • • • • •• 79 2 XVJCJC EFFECT OF CONCltNTRATION OF PHENETHYLBJCGUANJCDE ON JCNCO~PORATJCON OF LBUCINE-I-C14 JCNTO PROTEJCN OF JlJl~ ~JC"lt~ • • • • • • • • • • • • • • • • • • 80 XVIJCJC EFFECT or CONCENTRATJCON or TOLBUTAMIDE ON c1402 EVO~UT ION. • • • • • • • • • •• • • • • •• 81 XJCX ltPFECT OF CONCENTRATJCON OF TOLBUTAMIDE ON JCNCOR­ PORATION 0' LltUCJCNE-I-c14 JCNTO PROTEIN OF RAT LIVER. • • • • • • • • • • . • • • • • • • •• 82 :xx ErnCT OF GLUCOSE AND ORAL HYPOGLYCEMIC AGENTS 14 ON C 02 RELEASE • • • • • • • • • • • • • • •• 88 XXI EFFECT OF GLUCOSE AND ORAL HYPOGLYCEMIC AGENTS ON JCNCORPORATION OF LKUCIHE-c14 INTO PROTEIN .• 89 EFPICACY OF WASHINGS: LJCPOPROTEJCN. • • • • • • • • • • • • • • • • • • 92 XXJCJCJC EPFJCCACY OF WASHINGS: PROTEIN. • • • • • • • • • • • • • • • • • • • • 93 XXJCV EFFECT OP CONCENTRATJCON OF PHENETHYLBJCGUANIDE ON 14 C O2 RELEASE (EXPERIMENT 10). • • • • • • • •• 94 xxv EFFECT OF CONCENTRATJCON OF PHENETHYLBJCOUANJCDE ON JCNCORPORATJCON OF LEUCJCNE-I-c14 JClft'O PROTEIN OF RAT LIVER (EXPERIMBNT 10). • • • • • • • • • •• 95 LIST OF FIGURES FIGURE I THE STRUCTURE OF INSULIN. • • • • • • • • • • 1'7 II THE METABOLISM OF TOLBUTAMIDE • . • • • • • • 2 rr III STANDARD CURVE FOR PROTEIN ANALYSIS • • • • • • • 51 IV SELP-ABSORPTION CORRECTION CURVE FOR BaC0 . • . 54 3 V SEPARATION OF PROTEIN FRACTIONS • • • • • • • • • 64 VI THE CATABOLISM OF LEUCINE • . • • • • • • • • • • 69 VII INHIBITION OF C140 PRODUCTION FROM LEUCINE-1-C14 2 BY PHENETHYLBIGUANIDE • • • • • • • • • • • • • • 77 VIII COMPARISON OF INHIBITION OF C140 RELEASE FROM 2 LEUCINE-1-C14 BY TOLBUTAMIDE AND PHENETHYL- BIGUANIDE • • • • • • • • • • • • • • • • • • • • 83 IX COMPARISON OF INHIBITION OF PROTEIN SYNTHESIS BY TOLBUTAMIDE AND PHENETHYLBIGUANIDE. • • • • • •• 84 ABSTRACT The action of the hypoglycemi.c compounds, tolbutamide and phenethylbiguanlde, on protein biosynthesis was investigated by the use of rat liver homogenates, the necessary cofactors and 1euc1ne-c14. The results show that the incorporation of leuclne­ C14 into he~atic protein is inhibited by both compounds, though in a strikingly different manner. The inhibition by tolbutamide is linear with respect to concentration whereas the inhibition by phenethylbiguanide is not evident until a certain concentration is reached. At this pOint, the amount of incorporation decreases markedly until it levels off at a very low value. It has been postulated that there 1s some substance present which combines with phenethylblguanide and renders it inactive toward inhibition of protein synthesis. Glucose was investigated in tnis respect and found to have no effect on either tolbutamide or phenethyl­ biguanide induced inhibition. The catabolism of leucine was measured by the amount of C140 liberated in the course of the incubation. Both tolbutamide 2 and phenethylbiguanide were found to inhibit CO production. 2 Again, inhibition by tolbutamld.,3 was linear with respect to con­ centration. Phenethylbiguanld:a caused a pronounced initial inhi­ bition which tended to level off near the same concentration where the protein inhibition first occurs. This suggests that one of the reasons that low concentrations of PESO does not inhibit pro­ tein incorporation is due to the great decrease in leucine catab­ olism. Since less leucine is broKen down (catabolized), there is ecessarily more present to be incorporated
Recommended publications
  • (Trulicity) Pen and the Semaglutide (Ozempic) Pen
    Protocol H9X-MC-B021(b) Crossover Study Comparing Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen NCT03724981 Approval Date: 30-Nov-2018 H9X-MC-B021(b) Clinical Protocol Page 1 Protocol H9X-MC-B021(b): Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen Confidential Information The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of dulaglutide (LY2189265), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries. Dulaglutide (LY2189265) Eli Lilly and Company Indianapolis, Indiana USA 46285 Protocol Electronically Signed and Approved by Lilly on 07 Aug 2018 Amendment (a) Electronically Signed and Approved by Lilly on 11 Sep 2018 Amendment (b) Electronically Signed and Approved by Lilly on date below Approval Date: 30-Nov-2018 GMT LY2189265 H9X-MC-B021(b) Clinical Protocol Page 2 Table of Contents Section Page Protocol H9X-MC-B021(b): Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen ............................................................1 Table of Contents........................................................................................................................2 1.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Sulfonylurea Review
    Human Journals Review Article February 2018 Vol.:11, Issue:3 © All rights are reserved by Farah Yousef et al. Sulfonylurea Review Keywords: Type II diabetes, Sulfonylurea, Glimipiride, Glybu- ride, Structure Activity Relationship. ABSTRACT Farah Yousef*1, Oussama Mansour2, Jehad Herbali3 Diabetes Mellitus is a chronic disease represented with high 1 Ph.D. candidate in pharmaceutical sciences, Damas- glucose blood levels. Although sulfonylurea compounds are the cus University, Damascus, Syria. second preferred drug to treat Type II Diabetes (TYIID), they are still the most used agents due to their lower cost and as a 2 Assistant Professor in pharmaceutical chimestry, Ti- mono-dosing. Literature divides these compounds according to st nd rd shreen University, Lattakia, Syria their discovery into 1 , 2 , 3 generations. However, only six sulfonylurea compounds are now available for use in the United 3 Assistant Professor in pharmaceutical chimestry, Da- States: Chlorpropamide, Glimepiride, Glipizide, Glyburide, mascus University, Damascus, Syria. Tolazamide, and Tolbutamide. They function by increasing Submission: 24 January 2018 insulin secretion from pancreatic beta cells. Their main active site is ATP sensitive potassium ion channels; Kir 6.2\SUR1; Accepted: 29 January 2018 Published: 28 February 2018 Potassium Inward Rectifier ion channel 6.2\ Sulfonylurea re- ceptor 1. They are sulfonamide derivatives. However, research- ers have declared that sulfonylurea moiety is not the only one responsible for this group efficacy. It has been known that sud- den and acute hypoglycemia incidences and weight gain are the www.ijppr.humanjournals.com two most common adverse effects TYIID the patient might face during treatment with sulfonylurea agents. This review indi- cates the historical development of sulfonylurea and the differ- ences among this group members.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmacoepidemiological Study Report Synopsis ER-9489 A
    DAHLIA Report synopsis ER-9489 Version 1.0 14 November 2017 Pharmacoepidemiological study report synopsis ER-9489 A retrospective nationwide cohort study to investigate the treatment of type 2 diAbetic pAtients in Finland - DAHLIA Authors: Solomon Christopher, Anna Lundin, Minna Vehkala, Fabian Hoti Study ID: ER-9489 Sponsor: AstraZeneca Nordic Baltic Report version: 1.0 Report date: 14 November 2017 EPID ReseArch CONFIDENTIAL DAHLIA Report synopsis ER-9489 Version 1.0 14 November 2017 Study Information Title A retrospective nationwide cohort study to investigate the treatment of type 2 diabetic patients in Finland – DAHLIA Study ID ER-9489 Report synopsis version 1.0 Report synopsis date 14 November 2017 EU PAS register number ENCEPP/SDPP/8202 Sponsor AstraZeneca Nordic Baltic SE-151 85 Södertälje, Sweden Sponsor contact person Susanna Jerström, Medical Evidence Manager Medical Nordic-Baltic SE-151 85 Södertälje, Sweden Active substance ATC codes A10 (Drugs used in diabetes) Medicinal product The folloWing AstraZeneca products are available on the Finnish market: Bydureon (exenatide A10BX04), Byetta (exenatide A10BX04), Forxiga (dapagliflozin A10BX09), Komboglyze (metformine and saxagliptin A10BD10), Onglyza (saxagliptin A10BH03), Xigduo (dapagliflozin and metformin A10BD15) Country of study Finland Authors of the report Solomon Christopher, Anna Lundin, Minna Vehkala, Fabian Hoti synopsis EPID ReseArch Page 2 of 43 DAHLIA Report synopsis ER-9489 Version 1.0 14 November 2017 Table of contents 1 Study report summary (Abstract) ...........................................................................................
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • The Use of Sequential Pattern Mining to Predict Next Prescribed Medications ⇑ Aileen P
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Journal of Biomedical Informatics 53 (2015) 73–80 Contents lists available at ScienceDirect Journal of Biomedical Informatics journal homepage: www.elsevier.com/locate/yjbin The use of sequential pattern mining to predict next prescribed medications ⇑ Aileen P. Wright a, , Adam T. Wright b, Allison B. McCoy c, Dean F. Sittig d a Yale School of Medicine, New Haven, CT, United States b Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States c Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States d The University of Texas School of Biomedical Informatics at Houston and the UT-Memorial Hermann Center for Healthcare Quality & Safety, Houston, TX, United States article info abstract Article history: Background: Therapy for certain medical conditions occurs in a stepwise fashion, where one medication Received 13 March 2014 is recommended as initial therapy and other medications follow. Sequential pattern mining is a data Accepted 8 September 2014 mining technique used to identify patterns of ordered events. Available online 16 September 2014 Objective: To determine whether sequential pattern mining is effective for identifying temporal relation- ships between medications and accurately predicting the next medication likely to be prescribed for a Keywords: patient. Sequential pattern mining Design: We obtained claims data from Blue Cross Blue Shield of Texas for patients prescribed at least one Data mining diabetes medication between 2008 and 2011, and divided these into a training set (90% of patients) and Knowledge base Clinical decision support test set (10% of patients).
    [Show full text]
  • Assessment of Cardiovascular Effects of Non-Insulin Blood-Glucose-Lowering Agents Nelly Herrera Comoglio
    Assessment of cardiovascular effects of non-insulin blood-glucose-lowering agents Nelly Herrera Comoglio To cite this version: Nelly Herrera Comoglio. Assessment of cardiovascular effects of non-insulin blood-glucose-lowering agents. Human health and pathology. Université de Bordeaux, 2019. English. NNT : 2019BORD0355. tel-02969556 HAL Id: tel-02969556 https://tel.archives-ouvertes.fr/tel-02969556 Submitted on 16 Oct 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE PRÉSENTÉE POUR OBTENIR LE GRADE DE DOCTEUR DE L’UNIVERSITÉ DE BORDEAUX ÉCOLE DOCTORALE SPÉCIALITÉ PHARMACOÉPIDEMIOLOGIE Option Pharmaco-épidémiologie, pharmaco-vigilance Par Nelly Raquel HERRERA COMOGLIO TITRE : ÉVÉNEMENTS CARDIOVASCULAIRES MAJEURS ET MORTALITÉ EN PATIENTS TRAITÉS AVEC DES HYPOGLYCÉMIANTS NON INSULINIQUES Étude de cohortes basée sur une population de Catalogne, Espagne Sous la direction de : Xavier VIDAL GUITART Soutenue le 17 Décembre 2019 Membres du jury : Mme. AGUSTI ESCASANY, Antonia Prof. Fundacio Institut Catala de Farmacologia Président, rapporteur Mme. BOSCH Montserrat Prof. Associée Fundacio Institut Catala de Farmacologia Examinateur M. SALVO, Francesco Prof. Université de Bordeaux Examinateur Titre : ÉVÉNEMENTS CARDIOVASCULAIRES MAJEURS ET MORTALITÉ EN PATIENTS TRAITÉS AVEC DES HYPOGLYCÉMIANTS NON INSULINIQUES Étude de cohortes basée sur une population de Catalogne, Espagne Résumé : Le diabète mellitus Type 2 (DMT2) est une maladie chronique et progressive causée par multiples facteurs.
    [Show full text]
  • A Molecular Approach to the Modulation of Pharmacokinetics: Modification of Metabolic Conversion by Molecular Manipulation
    A MOLECULAR APPROACH TO THE MODULATION OF PHARMACOKINETICS: MODIFICATION OF METABOLIC CONVERSION BY MOLECULAR MANIPULATION E. J. ARIENS Farinacologisch Laboratoriu,n, Universiteit Nijinegen, Netherlands INTRODUCTION In pharmacology the interest in the question: "what are the effects of drugs?" has shifted more and more to the basic question: "how do drugs act?" Whatever the pharmacodynamic effect of a drug may be, it can only be due to an interaction between the molecules of the drug and the molecules constituting the biological object. Taking into account the usually small doses of drugs required to obtain responses, even in large animals, only an ex- tremely small fraction of the molecules in the biological object can be primarily involved in the drug action. An insight in the various types of molecular interactions in which the drug molecules take part in the body are an essential requisite in the rational approach to the development of new drugs. From a functional point of view the interactions of the drug molecules with all kinds of molecules in the biological object can be differentiated in different types, especially according to the molecular sites of action and the consequences of the interaction: 1. Those molecular sites of interaction which are directly and essentially involved in the induction of the effect. They usually are indicated as the sites of action for the drug. They are characteristic for the type of response, e.g. cholinergic, curariform, convulsant, antihistaminic, etc. 2. The molecular sites of interaction which are neither directly nor essentially involved in the induction of the effect, but which mainly influence the distribution of the drug over the various compartments.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A High-Content Screen for the Identification of Plant Extracts With
    pharmaceuticals Article A High-Content Screen for the Identification of Plant Extracts with Insulin Secretion-Modulating Activity Roland Hager 1 , Johannes Pitsch 1,2 , Jakob Kerbl-Knapp 1, Cathrina Neuhauser 1, Nicole Ollinger 2 , Marcus Iken 3, Josef Ranner 4, Verena Mittermeier-Kleßinger 4 , Corinna Dawid 4 , Peter Lanzerstorfer 1,* and Julian Weghuber 1,2,* 1 School of Engineering, University of Applied Sciences Upper Austria, 4600 Wels, Austria; [email protected] (R.H.); [email protected] (J.P.); [email protected] (J.K.-K.); [email protected] (C.N.) 2 FFoQSI—Austrian Competence Center for Feed and Food Quality, 3430 Tulln, Austria; [email protected] 3 PM International AG, 5445 Schengen, Luxembourg; [email protected] 4 Food Chemistry and Molecular Sensory Science, Technical University of Munich, 85354 Freising, Germany; [email protected] (J.R.); [email protected] (V.M.-K.); [email protected] (C.D.) * Correspondence: [email protected] (P.L.); [email protected] (J.W.); Tel.: +43-050-804-44402 (P.L.); +43-050-804-44403 (J.W.) Abstract: Bioactive plant compounds and extracts are of special interest for the development of pharmaceuticals. Here, we describe the screening of more than 1100 aqueous plant extracts and synthetic reference compounds for their ability to stimulate or inhibit insulin secretion. To quantify Citation: Hager, R.; Pitsch, J.; insulin secretion in living MIN6 β cells, an insulin–Gaussia luciferase (Ins-GLuc) biosensor was used. Kerbl-Knapp, J.; Neuhauser, C.; Positive hits included extracts from Quillaja saponaria, Anagallis arvensis, Sapindus mukorossi, Gleditsia Ollinger, N.; Iken, M.; Ranner, J.; sinensis and Albizia julibrissin, which were identified as insulin secretion stimulators, whereas extracts Mittermeier-Kleßinger, V.; Dawid, C.; Acacia catechu Myrtus communis Actaea spicata Vaccinium vitis-idaea Calendula officinalis Lanzerstorfer, P.; et al.
    [Show full text]
  • 2020 Diabetes Guideline Data Supplement
    Data Supplement Appendix A: Search strategies Table S1. Search strategies for systematic review topics Search dates – RCTs October 2018, Systematic reviews October 2018, Observational studies February 2019; Updated February 2020 Guideline chapter Comprehensive care in diabetes and CKD Systematic review topic RAS inhibitors in patients with diabetes and CKD Search strategy - 1. MeSH descriptor: [Angiotensin-Converting Enzyme Inhibitors] explode all trees CENTRAL 2. MeSH descriptor: [Angiotensin Receptor Antagonists] explode all trees 3. losartan:ti,ab,kw (Word variations have been searched) 4. irbesartan:ti,ab,kw (Word variations have been searched) 5. candesartan:ti,ab,kw (Word variations have been searched) 6. eprosartan:ti,ab,kw (Word variations have been searched) 7. valsartan:ti,ab,kw (Word variations have been searched) 8. olmesartan:ti,ab,kw (Word variations have been searched) 9. telmisartan:ti,ab,kw (Word variations have been searched) 10. captopril:ti,ab,kw (Word variations have been searched) 11. enalapril:ti,ab,kw (Word variations have been searched) 12. fosinopril:ti,ab,kw (Word variations have been searched) 13. lisinopril:ti,ab,kw (Word variations have been searched) 14. perindopril:ti,ab,kw (Word variations have been searched) 15. MeSH descriptor: [Diabetic Nephropathies] this term only 16. diabetic nephropath*:ti,ab,kw (Word variations have been searched) 17. diabetic kidney* or diabetic renal*:ti,ab,kw (Word variations have been searched) 18. MeSH descriptor: [Albuminuria] this term only 19. MeSH descriptor: [Proteinuria] this term only 20. proteinuria or albuminuria or microalbuminuria or macroalbuminuria:ti,ab,kw (Word variations have been searched) Search strategy - 1. exp Angiotensin-Converting Enzyme Inhibitors/ MEDLINE 2.
    [Show full text]